DK1401869T3 - Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 - Google Patents
Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1Info
- Publication number
- DK1401869T3 DK1401869T3 DK02734634T DK02734634T DK1401869T3 DK 1401869 T3 DK1401869 T3 DK 1401869T3 DK 02734634 T DK02734634 T DK 02734634T DK 02734634 T DK02734634 T DK 02734634T DK 1401869 T3 DK1401869 T3 DK 1401869T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- excretion
- molecules
- inhibiting germ
- kim
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29544901P | 2001-06-01 | 2001-06-01 | |
US29590701P | 2001-06-04 | 2001-06-04 | |
PCT/US2002/017402 WO2002098920A1 (en) | 2001-06-01 | 2002-05-31 | Molecules and methods for inhibiting shedding of kim-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1401869T3 true DK1401869T3 (da) | 2008-04-28 |
Family
ID=26969139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02734634T DK1401869T3 (da) | 2001-06-01 | 2002-05-31 | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7041290B2 (da) |
EP (1) | EP1401869B1 (da) |
JP (2) | JP4527394B2 (da) |
AT (1) | ATE382060T1 (da) |
AU (1) | AU2002305785B2 (da) |
CA (1) | CA2448427C (da) |
DE (1) | DE60224275T2 (da) |
DK (1) | DK1401869T3 (da) |
NZ (1) | NZ530457A (da) |
WO (1) | WO2002098920A1 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0907735T5 (da) * | 1996-05-24 | 2010-06-14 | Biogen Idec Inc | Modulatorer af vævsregenerering |
AU6986201A (en) * | 2000-06-16 | 2002-01-02 | Biogen Inc | Renal regulatory elements and methods of use thereof |
DE60224275T2 (de) * | 2001-06-01 | 2008-12-11 | Biogen Idec Ma Inc., Cambridge | Moleküle und verfahren zur inhibierung der freisetzung von kim-1 |
AU2013205381B2 (en) * | 2002-03-19 | 2016-04-14 | Celldex Therapeutics, Inc. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
AU2003299925B2 (en) * | 2002-12-30 | 2011-10-27 | Biogen Ma Inc. | KIM-1 antagonists and use to modulate immune system |
JP2007525434A (ja) * | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
AU2013242840B2 (en) * | 2003-03-19 | 2017-01-19 | Amgen Fremont Inc. | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
AU2006218489B2 (en) | 2005-03-02 | 2011-02-24 | Biogen Ma Inc. | KIM-1 antibodies for treatment of Th2-mediated conditions |
AU2006315580A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
WO2011079280A2 (en) | 2009-12-23 | 2011-06-30 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
KR20130005264A (ko) | 2010-01-11 | 2013-01-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-cd200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들 |
ES2552954T3 (es) | 2010-04-30 | 2015-12-03 | Alexion Pharmaceuticals, Inc. | Anticuerpos anti-C5a y métodos para el uso de los anticuerpos |
AU2012212066A1 (en) | 2011-02-03 | 2013-08-15 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
WO2013078089A1 (en) * | 2011-11-22 | 2013-05-30 | Biogen Idec Ma Inc. | Anti-tim-1 antibodies and uses thereof |
WO2015023836A1 (en) * | 2013-08-16 | 2015-02-19 | The Brigham And Women's Hospital, Inc. | Kim-1 as a therapeutic target in conditions associated with kidney fibrosis |
US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
US11541076B2 (en) | 2017-01-13 | 2023-01-03 | Celdara Medical, Llc | Chimeric antigen receptors targeting TIM-1 |
CN116693411A (zh) | 2017-04-28 | 2023-09-05 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
SG11202106987WA (en) | 2019-01-11 | 2021-07-29 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active agents |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
DK0907735T5 (da) * | 1996-05-24 | 2010-06-14 | Biogen Idec Inc | Modulatorer af vævsregenerering |
AU6986201A (en) * | 2000-06-16 | 2002-01-02 | Biogen Inc | Renal regulatory elements and methods of use thereof |
DE60224275T2 (de) * | 2001-06-01 | 2008-12-11 | Biogen Idec Ma Inc., Cambridge | Moleküle und verfahren zur inhibierung der freisetzung von kim-1 |
CA2452196A1 (en) * | 2001-06-29 | 2003-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes and methods of use thereof |
US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US7687454B2 (en) * | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
EP4091631A1 (en) * | 2002-01-30 | 2022-11-23 | The Brigham and Women's Hospital, Inc. | A tim-3 binding molecule for use in the treatment of a disease |
AU2003228336B2 (en) | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
JP2007525434A (ja) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
US20050119210A1 (en) | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
-
2002
- 2002-05-31 DE DE60224275T patent/DE60224275T2/de not_active Expired - Lifetime
- 2002-05-31 AU AU2002305785A patent/AU2002305785B2/en not_active Ceased
- 2002-05-31 CA CA2448427A patent/CA2448427C/en not_active Expired - Fee Related
- 2002-05-31 DK DK02734634T patent/DK1401869T3/da active
- 2002-05-31 WO PCT/US2002/017402 patent/WO2002098920A1/en active IP Right Grant
- 2002-05-31 JP JP2003502040A patent/JP4527394B2/ja not_active Expired - Fee Related
- 2002-05-31 EP EP02734634A patent/EP1401869B1/en not_active Expired - Lifetime
- 2002-05-31 AT AT02734634T patent/ATE382060T1/de not_active IP Right Cessation
- 2002-05-31 NZ NZ530457A patent/NZ530457A/en not_active IP Right Cessation
-
2003
- 2003-11-20 US US10/718,321 patent/US7041290B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/349,852 patent/US7300652B2/en not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/929,289 patent/US7696321B2/en not_active Expired - Lifetime
-
2010
- 2010-03-24 JP JP2010068988A patent/JP2010150291A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2448427C (en) | 2013-09-24 |
US20060153836A1 (en) | 2006-07-13 |
US20050112117A1 (en) | 2005-05-26 |
ATE382060T1 (de) | 2008-01-15 |
DE60224275D1 (de) | 2008-02-07 |
JP2010150291A (ja) | 2010-07-08 |
EP1401869B1 (en) | 2007-12-26 |
EP1401869A1 (en) | 2004-03-31 |
JP2005505256A (ja) | 2005-02-24 |
US7300652B2 (en) | 2007-11-27 |
US20080124336A1 (en) | 2008-05-29 |
EP1401869A4 (en) | 2005-10-19 |
WO2002098920A1 (en) | 2002-12-12 |
CA2448427A1 (en) | 2002-12-12 |
US7041290B2 (en) | 2006-05-09 |
JP4527394B2 (ja) | 2010-08-18 |
NZ530457A (en) | 2007-12-21 |
AU2002305785B2 (en) | 2008-01-17 |
DE60224275T2 (de) | 2008-12-11 |
US7696321B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1401869T3 (da) | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 | |
DK1171417T3 (da) | Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf | |
DK1211361T3 (da) | Momentmodstående stropforbindelse | |
NO20030856D0 (no) | Membranpenetrerende peptider og anvendelse av disse | |
DK2258168T3 (da) | Apparat til isolering af X-kromosombærende og Y-kromosombærende populationer af spermatozoer | |
DK1323222T3 (da) | Önet og fremgangsmåde til drift af et önet | |
CY1116768T1 (el) | Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων | |
TR200300478T2 (tr) | Hümanize antiLT-ß-R antikorları | |
DK1372686T3 (da) | Fremgangsmåder og sammensætninger til peptidsyntese | |
DK1553975T3 (da) | Optimerede Fc-varianter og fremgangsmåder til generering heraf. | |
DK1066049T3 (da) | Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse | |
DE122012000015I1 (de) | Peptidomimetika als protease inhibitoren. | |
DE60220529D1 (de) | Quantisiertes förderungssystem für 'solid free form fabrication' | |
DK0833839T3 (da) | Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme | |
ITRM20030376A1 (it) | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. | |
DK1437966T3 (da) | Måling af proteinsyntesehastigheder hos mennesker og i forsøgssystemer ved anvendelse af isotopisk mærket vand | |
DE60128652D1 (de) | Prostatischer stent zur erleichterung der drainage | |
MX2007011900A (es) | Sistema de celula reproductora. | |
DE60212910D1 (de) | Durchflusszellesystem zur Löslichkeitsprüfung | |
MA30265B1 (fr) | Procedes et compositions destines a cibler relt | |
DE50106206D1 (de) | Turbinenanlage | |
DK1484056T3 (da) | Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse | |
DK1392822T3 (da) | Dobbelttransficeret cellelinie anvendelig til identifikation af transporthæmmere | |
ATE288148T1 (de) | Zweidimensionale pyramidenfilterarchitektur | |
DK1316239T3 (da) | Höreapparat og fremgangsmåde til fremstilling af samme |